Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

• Status: Completed
• Trial end date: 2017-04-21

Summary

This phase I trial studies the side effects and best dose of dalteparin when given together with sunitinib malate in treating patients with kidney cancer that has spread to other parts of the body or cannot be removed by surgery. Anticoagulants, such as dalteparin, help prevent blood clots and have been shown to increase survival in patients with cancer. Anticoagulants may also prevent the formation of new blood vessels. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by inhibiting new blood vessels and blocking blood flow to the tumor. Giving dalteparin together with sunitinib malate may starve tumors and kill more tumor cells.

• Phase: Phase 1

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Collaborators: National Cancer Institute (NCI); Pfizer
• Treatments: Dalteparin; Heparin, Low-Molecular-Weight; Sunitinib; Tinzaparin